Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...
Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ...
March 12, 2026 7:30am EDT Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ...
We are curing more cancers than we used to,” Cottrill said. “Recurrent cancers are more challenging to cure than cancers that ...
6hon MSN
Why some breast cancers spread faster: Jagged1 may trigger a tissue-stiffening feedback loop
A research group led by Professor Cecilia Sahlgren at Åbo Akademi University (Finland) and the InFLAMES Research Flagship has ...
2d
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for ...
Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.
Dogs are more than just sweet, furry friends that keep us company, it turns out they can be hugely beneficial for our health ...
Cancer remains one of the most serious health challenges in the world. It occurs when cells in the body begin to grow ...
A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast ...
In an interview with Targeted Oncology, Natalie Berger, MD, hematologist and oncologist at the New York Presbyterian Medical Group, discusses some of the most exciting areas of breast cancer research, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results